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Objective. To determine the factors leading to in-hospital mortality within 28 days in hospitalized patients with ARDS. It was a
prospective observational cohort study conducted in Intensive Care Unit of Aga Khan University Hospital Karachi from March
to August 2011. Methodology. Data was collected from patients admitted in the intensive care unit on the basis of inclusion and
exclusion criteria.The patients were followed daily for 28 days to record any in-hospital complications and the outcome of patients.
Results. Total of 46 patients were included during this period out of which 56% (26)weremales and 43% (20)were females.Mean age
was 44 ± 19 years. There were 11 (23.9%) patients with age >65 and 35 (76%) had age <65 years. There were 21 (45.6%) patients with
pulmonary ARDS and 25 (54.3%) had extrapulmonary ARDS. APACHE II score of >20 was present in 23 (50%) patients while the
rest had score of <20. Regarding in-hospital complications, 23 (50%) patients developed sepsis, 31 (67.4%) hadmultiorgan failure, 14
(30%) had refractory shock, and 15 (32.6%) developed refractory hypoxemia. Out of 46 patients, 26 (56.5%) died within 28 days. On
univariate analysis, high APACHE score, multiorgan failure, refractory shock, and refractory hypoxemia weremain causes of death.
Conclusion. ARDS is a syndrome of high mortality with mortality rate of 56.5% in this study. High APACHE, sepsis, multiorgan
failure, refractory shock, and refractory hypoxemia are the leading causes of death in our patients.
1. Introduction
Acute respiratory distress syndrome (ARDS) is a form of
severe hypoxemic respiratory failure characterized by bilat-
eral lung infiltrates with no clinical or objective evidence of
left heart failure [1].This syndrome is among themajor causes
of morbidity and mortality in intensive care units (ICUS)
worldwide. Even with optimal conventional therapies, the
reported mortality rates in various studies vary from 30%
to 70% [2, 3]. It can be caused by either direct or indirect
insult to lung, hence, has been classified as pulmonary ARDS
and extrapulmonary ARDS, respectively. This division is
thought to have significant clinical implications as patients
might respond differently to various treatments including
mechanical ventilation [4, 5]. However, further studies [6]
have failed to show any reproducible difference.Many studies
have sought to identify factors during the acute illness that
predict mortality [6–8]. These factors can be categorized
as patient-, disease-, or treatment-related ones. Regarding
patient-related factors older patients (age >65 yrs) and male
gender (66%) are associated with increased death rates with
ARDS [8–10]. Disease-related factors predicting mortality in
various studies are underlying cause of ARDS [11], Acute
Physiology and Chronic Health Evaluation (APACHE) [12],
and in-hospital complications like sepsis [8], multiorgan
failure (MOF), refractory shock, and refractory hypoxemia
[13]. Among treatment-related factors protective ventilatory
strategies have been shown to improve outcome in patients
with ARDS [14].
Although ARDS is well studied worldwide, but no local
data is available to document the factors associated with
mortality in ARDS and difference in outcome in patients with
pulmonary and extra pulmonary ARDS. Early identification
of these factors will help to assess prognosis and aid in timely
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management. So the aim of this study is to evaluate the
factors associated with mortality in our patients presented
with ARDS.
2. Methodology
This was a prospective observational cohort study conducted
in ICU of Agha Khan University hospital Karachi from
March toAugust 2011. Study subjects include all adult patients
(age greater than 14) with admitting diagnosis of ARDS.
The patients with history or clinical evidence of congestive
cardiac failure, patients with a do-not resuscitate order at
ICU admission, or who died within 24 hrs of ARDS diagnosis
were excluded from the study. ARDS was defined according
to American-European Consensus Conference criteria (1):
acute onset, PaO
2
/FiO
2
of ≤200, and bilateral infiltrates on
chest radiograph. Exclusion criteria were an occlusion pres-
sure of ≥18mmHg or clinical heart failure. Etiology of ARDS
was broadly classified into pulmonary ARDS (which include
any of these: pneumonia, aspiration pneumonia, inhalation
injury, or lung contusions) and extra pulmonary ARDS
(which include any of these: sepsis, pancreatitis, postblood
transfusions, major trauma, or adverse reaction of drug). We
prospectively identified variables that could be independently
associatedwithmortality: age, gender, etiology ofARDS, high
acute physiology and chronic health evaluation II (APACHE
II) score, sepsis, multiorgan failure (MOF), refractory shock,
and refractory hypoxemia.Webroadly divide age into groups,
that is, age >65 and age <65. APACHE score was also
divided into two groups, that is, >20 and <20. Sepsis [15]
was clinically recognized by the presence of two or more
of the following: temperature >38.5∘C or <35∘C, heart rate
>90 beats/min, respiratory rate >20 breaths/min or PaCO
2
<
32mmHg, WBC > 12,000 cells/mm3, <4000 cells/mm3 and
are due to infection (culture or Gram stain of blood, sputum,
urine, or normally sterile body fluid positive for pathogenic
microorganism). Multiorgan failure [25] is defined to have
presence of any of these in addition to ARDS—(1) acute
renal failure: within 48 hours absolute increase in the serum
creatinine concentration of ≥0.3mg/dL from baseline, or
oliguria of less than 0.5mL/kg per hour for more than six
hours, (2) cardiac arrest: reversible ventricular fibrillation
or asystole, (3) CNS involvement: neuroimaging proven
ischemic or hemorrhagic stroke or Glasgow coma scale
<8 for ≥3 days, and (4) acute hepatic failure: bilirubin
>5.0mg/dL and prothrombin time or partial thromboplastin
time >1.5 times control. Refractory shock was defined as
need for dopamine at >15mcg/kg/min, or norepinephrine
or epinephrine at >0.25mcg/kg/min to maintain mean BP
at >60mmHg. Refractory hypoxemia was defined as being
unable to maintain PaO
2
> 60mmHg despite being on
maximum ventilator support. The outcome measure was in-
hospital mortality within 28 days.
Datawas collected frompatients admitted in the intensive
care unit on the basis of inclusion and exclusion criteria.
The purpose of the study was explained to the patients or
next of kin of the patients and informed consent was taken.
The age, gender, etiology, and APACHE score on day 1 were
noted. The patients were followed daily for 28 days to record
any in-hospital complications leading finally to in-hospital
mortality.
3. Statistical Analysis
Data was analyzed by using SPSS (Statistical Package for
Social Sciences) version 19.0. A descriptive analysis was done
for qualitative variables, that is, pulmonary ARDS, extra
pulmonary ARDS, age (<65 or >65), APACHE score (<20 or
>20), presence or absence of sepsis,multiorgan failure, refrac-
tory shock, and refractory hypoxemia, and was presented as
frequency (percentage). Frequency of outcome variable, that
is, mortality, was calculated and cross-tabulation was done
between outcome variable and different factors. Differences
between survivors and nonsurvivors were explored with chi-
square test. A 𝑃 value of <0.05 was considered significant.
4. Results
A total of 46 patients were included in this study on the basis
of inclusion and exclusion criteria during 6-month period.
Mean age was 44 ± 19 years. Out of 46 patients 11 (23.9%)
had age greater than 65 years and 35 (76%) had age less
than 65. There was slight male dominance in this cohort
with 26 (56.5%) were males and 20 (43.5%) were females.
Heart failure was excluded clinically and none of the patients
underwent pulmonary artery catheterization.
The causes of ARDS are shown in Figure 1. The predomi-
nant etiology was extra pulmonary ARDS, that is, 25 (54.3%).
Interestingly 23 (50%) of patients had APACHE score of >20
and the rest had score of less than 20. Regarding in-hospital
complicationsmultiorgan failure was the predominant one 31
(67.4%) followed by sepsis 23 (50%), refractory hypoxemia 15
(32.6%), and refractory shock 14 (30%).
The primary outcome measure, that is, mortality, was
56.5% (𝑛 = 26). Mortality was higher in patients with
pulmonary ARDS but did not reach the statistical signifi-
cance. Out of 26 patients who died 14 (53.8%) patients had
pulmonary ARDS while 12 (46.2%) patients belonged to
extra pulmonary group. Comparison of risk factors of among
survivors and non survivors is presented in Figure 2.
Therewas no significant difference between survivors and
non survivors in sex distribution and age. Similarly sepsis was
common among non survivors but did not reach the statisti-
cal significance 16 (61.5%, 𝑃 value 0.07). Factors significantly
associated with mortality (Table 1) were APACHE score of
>20 (𝑃 = 0.003), multi organ failure (𝑃 ≤ 0.001), refractory
shock (𝑃 ≤ 0.001), and refractory hypoxemia (𝑃 ≤ 0.001).
5. Discussion
This was a small study done in a single tertiary care center in
Karachi. In our study of 46 patients, the mortality rate was
56%. In past two decades there are studies from world best
centers claiming that mortality has decreased to up to 30%
[16, 17], which may have been a result of improvement in the
specific management of patients with ARDS as well as in the
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Figure 1: Frequency of causes of ARDS.
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Figure 2: Comparison of risk factors among survivors and non
survivors.
general management of ICU patients. But in this same era
of lung protective ventilatory strategy, there are other studies
[2, 18] still reporting mortality rate of 58%. In recent years
there is increasing interest worldwide to find the individual
predictors of mortality in ARDS.
A large number of these studies have been performed
in Caucasians. Only a few studies are available from Asian
countries including India. In Pakistan, to our knowledge,
so far no study has been published on ARDS and mortality
Table 1: Univariate analysis of risk factors of mortality.
Characters Survivors Non survivors P-value
Age
>65 Y 10% (N = 2) 34.6% (N = 9) 0.08
<65 Y 90% (N = 18) 65.4% (N = 17)
Gender
Male 45% (N = 9) 65.4% (N = 17) 0.16
Female 55% (N = 11) 34.6% (N = 9)
APACHE
>20 25% (N = 5) 69.2% (N = 18) 0.003
<20 75% (N = 15) 30.8% (N = 8)
Sepsis 35% (N = 7) 61.5% (N = 16) 0.07
MOF (Multi organ failure) 35% (N = 7) 92.3% (N = 24) <0.001
Refractory shock 0 53.8% (N = 14) <0.001
Refractory hypoxemia 0 57.7% (N = 15) <0.001
secondary to it. In consideration of thismarked heterogeneity
among studies, making a comparison of results from this
study with the previously published literature is a challenging
task.
The age distribution of patients among studies is variable.
In some studies the majority of patients were younger, below
60 years of age [6], while others comprise elderly patients in
majority [9, 19]. In our study 76% of the patients were below
65 years. This is maybe due to the fact that with such limited
resources, younger population has better access to treatment
facilities as compared to older population who are treated
conservatively rather than shifting to ICU. Although patients
with age above 65 years accounted for only 24% of study
subjects (11/46), there was a suggestion of increasedmortality
compared with those below 65 years: 81.8% (9/11) versus
48.5% (17/35), respectively. So our results are consistent
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with previous studies, suggesting old age as risk factor for
mortality in ARDS.
Male gender is associated with higher mortality rate with
ARDS as assessed by International Classification of Diseases,
Ninth Revision codes on death certificates [20]. This may be
because of genetic factors that predispose to ARDS, because
of differences in susceptibility to risk factors for ARDS or
hormonal difference. Moss and Mannino have shown in
their study that mortality rate is higher in male patients
as compared to females [20]. They attribute it to genetic
difference or response to the therapy. In a study by Seeley et
al. [21], mortality rates were higher among females 51% versus
36%. However, in a study in India the mortality rates were
again higher among men, that is, 57% [6]. However, in our
study there is near equal gender distribution among survivors
and non survivors.
Although it has been hypothesized that mortality among
patients should be higher because of the direct lung injury
and has been supported by a number of studies [4, 22].
A meta-analysis [23] and Agarwal and colleagues [6] did
not find any difference in mortality among patients with
pulmonary ARDS versus extra pulmonary ARDS. Even in
our study there is near equal distribution of pulmonary and
extrapulmonary ARDS among survivors and non survivors.
In our study higher APACHE ll score representing sever-
ity of disease was significantly associated with mortality—an
observation consistent with previous studies [18, 21].
It has been said that most improvement in ARDS survival
observed over the past 20 years is explained by reduced
case fatality in patients with a risk factor other than sepsis.
Worldwide sepsis along with MOF and refractory shock has
been leading cause of death in patients with ARDS [13, 18,
25]. In this study although MOF and refractory shock were
significantly associated with mortality, but this was not the
case with sepsis. Sepsis either as etiology or developed as
an in-hospital complication though was found more in non
survivors than survivors but trend did not reach statistical
significance. On the contrary, in this study none of the
patients developing refractory shock survived.
Interestingly refractory hypoxemiawas significantly asso-
ciated with mortality in this cohort and as is the case with
refractory shock, none of the patients with refractory hypox-
emia survived. It was present in 57.7% of non survivors—
a finding inconsistent with rest of the studies. In 1985,
Montgomery et al. [24] reported that refractory hypoxemia
was the cause of death in less than 20% of patients with
ARDS. Further studies showed similar results, [18, 25, 26]
supporting the concept that ARDS is rarely, by itself, a
cause of death. Although we in our institution use lung
protective ventilatory strategy as the standard of care, but
the reason behind this observation is unclear. This may
be due to the fact that our institution lacks the facilities
of extracorporeal membrane oxygenation (ECMO), inhaled
nitric oxide, partial liquid ventilation, or surfactant which
though failed to show consistent survival benefit in studies do
show improvement in individual cases. However, it requires
further clarification.
Recently, a New Berlin definition of ARDS [27] has been
proposed which is endorsed by European Society of Intensive
Care Medicine, the American Thoracic Society (ATS), and
the Society of Critical Care Medicine (SCCM). According to
it, the onset of ARDSmust be acute, with bilateral lung opac-
ities on chest X-ray and respiratory failure simply being not
fully explained by cardiac failure or fluid overload. There is
no need to exclude heart failure in the new ARDS definition.
Three categories were developed on the basis of hypoxemia:
mild (PaO
2
/FiO
2
≤ 300mmHg but >200mmHg), moder-
ate (PaO
2
/FiO
2
≤ 200mmHg but >100mmHg), or severe
(PaO
2
/FiO
2
≤ 100mmHg), all on positive end expiratory
pressure (PEEP) of 5+.These groups, according to consensus
panel, were associated with increased mortality (27%, 32%,
and 45%, resp.). As we recruited patients on the basis of older
definition so we did not categorize them intomild, moderate,
and severe groups and also did not include the ventilatory
parameters, which definitely is a limitation to our study in
view of current definition.
Apart from the above mentioned, there were certain
other limitations of our study. It was a single centre study.
Sample size was small and because of small sample size only
univariate analysis was possible, and we cannot calculate
the independent risk factor of mortality using multivariate
analysis.
6. Conclusion
ARDS is a syndrome associated with high mortality among
ICU patients. In this study the mortality rate was 56%. Age,
gender, and etiology of ARDS and sepsis were equally dis-
tributed among survivors and nonsurvivors. High APACHE
score, multiorgan failure, and refractory shock were asso-
ciated with high mortality as in previous studies. On the
contrary to most of the other recent studies, refractory
hypoxemia was found to be a leading cause of death in this
group of patients.
Because of small sample size these results are not gen-
eralizable, but yet to our knowledge this is the first study
in Pakistan on this subject. Further studies are required
preferably multicentre and with large sample size to make
these results meaningful.
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